Search results
Showing 1201 to 1215 of 1423 results for primary care
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.
In development Reference number: GID-TA11277 Expected publication date: TBC
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.
clear evidence base for rapid genetic testing at the time of diagnosis of primary breast cancer. Knowledge of genetic status may...
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Discontinued Reference number: GID-TAG402
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
Discontinued Reference number: GID-TA10271
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy